Head-to-head comparison of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in advanced pancreatic cancer: a target trial emulation using real-world data-Reference-Cited by-同舟云学术

Head-to-head comparison of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in advanced pancreatic cancer: a target trial emulation using real-world data

Published:2023-02 Issue: Volume:78 Page:28-34
ISSN:1047-2797
Container-title:Annals of Epidemiology
language:en
Short-container-title:Annals of Epidemiology

Author:

Boyne Devon J.,Brenner Darren R.,Gupta Alind,Mackay Eric,Arora Paul,Wasiak Radek,Cheung Winson Y,Hernán Miguel A.

Funder

Canadian Institutes of Health Research

Alberta Cancer Foundation

Publisher

Elsevier BV

Subject

Epidemiology

Reference42 articles.

1. Projected estimates of cancer in Canada in 2020;Brenner;CMAJ,2020

2. Canadian cancer statistics 2019 toronto,2019

3. Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations;Huang;Gut,2019

4. Evolving treatment landscape for early and advanced pancreatic cancer;Lau;World J Gastrointest Oncol,2017

5. Cancer statistics, 2020;Siegel;CA Cancer J Clin,2020

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Head‐to‐head comparison of treatment sequences in advanced pancreatic cancer—Real‐world data from the prospective German TPK clinical cohort study;International Journal of Cancer;2024-07-02

2. The Clone-Censor-Weight Method in Pharmacoepidemiologic Research: Foundations and Methodological Implementation;Current Epidemiology Reports;2024-02-17

3. How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy?;BMC Health Services Research;2023-05-13